Verrucae are hyperkeratotic lesions found particularly over the pressure areas of the feet (heel and ball). They are also known as verrucae plantaris, or plantar warts. They are usually self-limiting but may be treated if symptomatic.
By James Heilman, MD, via Wikimedia Commons
Verrucae are caused by the human papillomavirus (HPV), types 1, 2, 4, 27 and 57. They affect epithelial cells causing small rough papules. Replication of the virus within the epithelial cells causes a proliferative reaction and formation of plaque or papule. Incubation is very variable, ranging from one month to over a year.
HPV infection is acquired from direct contact with an affected individual or from the environment (eg, from contaminated floors in places such as communal showers and changing areas or swimming pools). Damaged or wet skin predisposes to infection. It appears the virus can survive outside the body for a significant length of time, probably months or even years.
They should not be used as a reason to stop children swimming, as learning to swim is important in the National Curriculum and helps to prevent death from drowning.
Warts are very common and thought to affect 7-12% of the population. No large studies are available; however, small studies suggest up to 30% of children and young adults may have warts. There are no high-quality epidemiological studies on prevalence of verrucae specifically.
Verrucae are more common in young people regularly using swimming pools and communal washing/changing areas.
- They may cause pain, particularly with walking.
- Occasionally leg or back pain may result from altered posture or gait disturbance.
- They are more common in the immunosuppressed:
- Long-term immunosuppressant usage.
- Transplant patients.
- Lymphomas and leukaemias.
- Firm, hyperkeratotic lesions.
- May have minor pinpoint petechiae centrally within the lesions. These may appear as small black dots.
- Usually found over pressure areas.
- Flat because of pressure.
- May fuse with surrounding warts (mosaic warts - below).
Diagnosis is made by examination and observation of typical features.
- Corns: these are inflamed and painful. Paring corns reveals pearly sections of keratin.
- Calluses: these are thick and painless patches of hard skin.
- Black heel: patches of hard skin with ruptured capillaries.
- Verrucous squamous cell carcinoma: this should be considered if long-standing. They invade the dermis but are slow-growing and rarely metastasise.
- Actinic keratosis.
- Lichen nitidus.
- Lichen planus.
- Seborrhoeic keratosis.
- Malignant melanoma.
None are usually required or appropriate. Distinguishing them from corns may require paring of the keratin. Blood tests to check for causes of immunodeficiency may be required in unusually widespread or resistant cases.
Treatment is not necessarily required if the verruca is not painful. However, a wart on the sole of the foot is more likely to cause discomfort than warts in other areas such as the hands.
Topical salicylic acid has the best evidence base and is cheap. It is therefore normally first-line treatment. There is no evidence for one preparation being more effective than another. The wart should be pared down prior to application. Daily treatment for at least 12 weeks is required.
Cryotherapy with liquid nitrogen every two weeks until the wart has gone (up to four months) may be effective. For plantar warts, there is evidence that this is more effective if the lesion is pared down first. Clinicians vary in how long they freeze the wart for; usually liquid nitrogen is applied until a ring of frozen tissue is visible around the wart, typically 5 to 30 seconds. There is no evidence that a spray or cotton bud application is more effective. Over-the-counter preparations do not reach such low temperatures and are probably not as effective. Reported cure rates vary hugely. Cryotherapy may be painful, may cause blistering and should be avoided in young children.
Cryotherapy may be used in combination with topical salicylic acid. The latter is applied in between episodes of cryotherapy, once the blistering has settled down.
Other treatments with some evidence base recommended as options by the British Association of Dermatologists (BAD) guidelines include:
- 5-fluorouracil (5-FU)
- Photodynamic therapy
- Topical immunotherapy
These would be carried out in secondary care. Secondary care referral may be necessary in the following situations:
- Multiple verrucae or mosaic warts.
- Immunocompromised patients.
- Uncertain diagnosis.
- Symptomatic verrucae resistant to treatment in primary care.
Patients with diabetes who have verrucae should be referred to a diabetic foot clinic.
- Secondary to condition or treatment:
- Scars and keloid formation.
- Malignant change: extremely rare, especially with normal immunity. Whilst it rarely occurs, be aware of the possibility in patients who are immunocompromised (for example, transplant patients).
Many verrucae will resolve without treatment but this may take some years. Many studies show high resolution rates in the placebo groups. One study showed in schoolchildren, half resolved within one year and two thirds within two years.This may take longer in adults. Those with immunosuppression may be resistant to treatment.
Suggestions for reducing spread include:
- Cover the verruca with a waterproof plaster when swimming. Swimming socks have no value other than in attracting attention and increasing stigma and should not be encouraged.
- Wear flip-flops in communal areas and showers.
- Avoid sharing shoes, socks or towels.
- Limit auto-inoculation by avoiding trauma (scratching and biting), keeping feet dry and changing socks or tights daily.
Did you find this information useful?
- Lynch MD, Cliffe J, Morris-Jones R; Management of cutaneous viral warts. BMJ. 2014 May 27 348:g3339. doi: 10.1136/bmj.g3339.
- British Association of Dermatologists Guidelines for the management of cutaneous warts (2014); British Journal of Dermatology, July 2014
- Brenner RA, Taneja GS, Haynie DL, et al; Association between swimming lessons and drowning in childhood: a case-control Arch Pediatr Adolesc Med. 2009 Mar 163(3):203-10.
- Kwok CS, Gibbs S, Bennett C, et al; Topical treatments for cutaneous warts. Cochrane Database Syst Rev. 2012 Sep 12 9:CD001781. doi: 10.1002/14651858.CD001781.pub3.
- Warts and verrucae; NICE CKS, December 2014 (UK access only)
- Bruggink SC, Eekhof JA, Egberts PF, et al; Natural course of cutaneous warts among primary schoolchildren: a prospective cohort study. Ann Fam Med. 2013 Sep-Oct 11(5):437-41. doi: 10.1370/afm.1508.
- Verrucas; British Swimming